LABRHA participated at the ACR Congress in Washington DC, which took place from the 11th to the 16th of November 2016, and displayed a poster presenting the results of a study conducted to identify the clinical and radiological factors associated with a lack of a relevant response to viscosupplementation (VS) according to OMERACT-OARSI criteria after injections of HAppyVisc® in symptomatic knee OA patients.
166 patients with available data from the intent-to-treat population (n=205) of HAV-2012 study have been included.
At inclusion, investigators recorded:
- demographic, anthropometric, clinical data (patient global assessment, WOMAC, knee effusion)
- radiologic data (tibiofemoral joint space narrowing according to OARSI grade, patellofemoral OA).
Patients received 3 weekly IA injections of HAppyVisc®.
At 6-month of follow-up, VS response was defined according to OMERACT-OARSI criteria.
.
This study showed:
- Radiological severity and obesity may be predictors of a lack of a relevant response after VS.
- Disease duration and symptom severity did not alter the response to VS.
- A more stringent selection of patients eligible for HA injection could optimize the effectiveness of treatment and limit the number of VS injections in those with risk factors for poor outcome.
This finding may impact our daily practice and help in considering VS in future international recommendations.
